Physician profile
Justin A Schweitzer
NPI 1023047867
$753,482.12
in general payments reported to CMS, 2019-2025
35 companies · $154K in 2025
The $154K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $102K · 2021: $84K · 2022: $115K · 2023: $102K · 2024: $140K · 2025: $154K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $132K · Consulting Fee: $117K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Travel and Lodging: $29K · Food and Beverage: $13K · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $132,175.00 |
| Consulting Fee | $117,426.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,240.00 |
| Travel and Lodging | $28,696.12 |
| Food and Beverage | $13,375.21 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $138,402.06 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $96,992.51 | 2021-2025 | Durysta, Vuity, Lumigan |
| Allergan, INC. | $93,035.89 | 2019-2022 | |
| Reichert, INC. | $73,400.00 | 2019-2025 | Tono-Vera Tonometer US Starter Kit Human Rechargable |
| Dompe US, INC. | $51,740.87 | 2019-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $50,959.43 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $50,377.98 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $33,431.28 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Alcon Vision LLC | $25,742.30 | 2019-2025 | Rhopressa, Tryptyr, Argos |
| Glaukos Corporation | $24,791.35 | 2019-2025 | Istent Trabecular Micro-Bypass Stent System, Kxl System, Ce-Marked Kxla System |
| Sight Sciences, INC. | $23,977.92 | 2019-2025 | Tearcare System, Omni Surgical System |
| Lkc Technologies, INC. | $17,298.94 | 2020-2024 | |
| Konan Medical USA, INC. | $13,000.00 | 2020-2024 | |
| Harrow Eye, LLC | $11,541.44 | 2024-2025 | Vevye, Natacyn, Ilevro |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $9,806.26 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $9,477.50 | 2019-2025 | Rhopressa, Rocklatan |
| Carl Zeiss Meditec, INC. | $7,748.22 | 2019-2025 | Cirrus Hd-Oct, Clarus, Forum |
| Novartis Pharmaceuticals Corporation | $4,867.33 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $3,650.21 | 2019-2024 | Tecnis Iol, Healon Duet Pro, Tecnis Iol |
| Topcon Healthcare, INC. | $2,325.40 | 2024 | |
| Thea Pharma INC. | $2,282.93 | 2023-2024 | Iyuzeh |
| Quidel Corporation | $1,971.04 | 2019-2022 | |
| Oyster Point Pharma, INC. | $1,234.37 | 2022-2025 | Tyrvaya, Phentolamine Mesylate, Ryzumvi |
| Kala Pharmaceuticals, INC. | $1,226.96 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $1,116.91 | 2022-2025 | Cirrus Hd-Oct, Quatera 700, Cirrus 6000 With Angioplex |
| Tearlab Corp | $1,020.42 | 2022-2024 | Scoutpro Osmolarity System |
| Eyepoint US, INC. | $854.00 | 2019 | |
| Eyevance Pharmaceuticals LLC | $289.23 | 2019-2021 | |
| Horizon Therapeutics Plc | $288.74 | 2019-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $187.18 | 2022 | |
| Ocular Therapeutix, INC. | $154.96 | 2020-2023 | Dextenza |
| Amgen INC. | $132.73 | 2024 | Tepezza |
| Biotissue Holdings INC. | $90.13 | 2023-2025 | |
| Shire North American Group INC | $35.75 | 2019 | |
| Rxsight INC | $29.88 | 2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,383.50 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Schweitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.